TNFRSF1B and ovarian carcinoma: Previous studies have shown that using antagonistic antibodies to target TNFR2 can suppress the proliferation of ovarian cancer cells and tumour‐associated regulatory T cells [38], highlighting a dually beneficial effect of boosting antitumor immune response and inhibiting tumour cells proliferation.